Evidence map›Paper›PMID 41799779›Full record

ArticleInternational journal of medical sciences2026

A prognostic 19-gene signature and LBP-mediated immune dysregulation define the tumor microenvironment in poor-prognosis KIRC.

Chia-Hung Chen, Hsiao-Hsuan Huang, Tzu-Han Weng, Ta-Wei Kuo, Nien-Che Ho, Kai-Yao Huang, Hui-Ju Kao, Chen-Lin Yu, Shun-Long Weng, Kuang-Wen Liao

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Chia-Hung ChenDepartment of Medical Research, Hsinchu MacKay Memorial Hospital, Hsinchu City 30071, Taiwan, ROC.
Hsiao-Hsuan HuangIndustrial Development Graduate Program of College of Engineering Bioscience, National Yang Ming Chiao Tung University, Hsinchu City 30068, Taiwan, ROC.
Tzu-Han WengDepartment of Dermatology, MacKay Memorial Hospital, Taipei City 10449, Taiwan, ROC.
Ta-Wei KuoDepartment of Biological Science and Technology, College of Engineering Bioscience, National Yang Ming Chiao Tung University, Hsinchu City 30068, Taiwan, ROC.
Nien-Che HoDepartment of Biological Science and Technology, College of Engineering Bioscience, National Yang Ming Chiao Tung University, Hsinchu City 30068, Taiwan, ROC.
Kai-Yao HuangDepartment of Medical Research, Hsinchu MacKay Memorial Hospital, Hsinchu City 30071, Taiwan, ROC.
Hui-Ju KaoDepartment of Medical Research, Hsinchu MacKay Memorial Hospital, Hsinchu City 30071, Taiwan, ROC.
Chen-Lin YuDepartment of Medical Research, Hsinchu MacKay Memorial Hospital, Hsinchu City 30071, Taiwan, ROC.
Shun-Long WengDepartment of Biological Science and Technology, College of Engineering Bioscience, National Yang Ming Chiao Tung University, Hsinchu City 30068, Taiwan, ROC.
Kuang-Wen LiaoDepartment of Biological Science and Technology, College of Engineering Bioscience, National Yang Ming Chiao Tung University, Hsinchu City 30068, Taiwan, ROC.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Kidney renal clear cell carcinoma (KIRC) exhibits pronounced immune heterogeneity, and immune dysregulation within the tumor microenvironment (TME) contributes to poor outcomes. Leveraging TCGA-KIRC RNA-seq, we stratified patients by immune-cell infiltration and immune-regulatory gene expression to define a poor-survival subgroup for discovery. Differential expression analysis prioritized lipopolysaccharide-binding protein (LBP) and generated an immune-relevant candidate set that was refined from 406 to 87 genes by stepwise logistic regression and then benchmarked through one million random 20-gene models, yielding a final 19-gene prognostic signature. Six immune-cell features associated with survival were identified, including higher M0 macrophages, regulatory T cells, activated CD4 memory T cells, plasma cells, and neutrophils (worse prognosis) and resting mast cells (better prognosis). LBP was highly expressed in the poor-survival subgroup and functionally validated

Indexed as

Acute-Phase ProteinsBiomarkers, TumorCarcinoma, Renal CellCarrier ProteinsKidney NeoplasmsMembrane GlycoproteinsTumor MicroenvironmentFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHumansKidneyLipopolysaccharide-Binding ProteinPrognosisAcute-Phase ProteinsBiomarkers, TumorCarrier ProteinsLipopolysaccharide-Binding ProteinMembrane Glycoproteinskidney renal clear cell carcinoma (KIRC)lipopolysaccharide-binding protein (LBP)prognostic gene signaturetumor microenvironment (TME)

Identifiers

PMID41799779
PMCPMC12964576

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.